Clinical trialsCompany release

Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027

🇺🇸 Curis Inc (CRIS) · Fri 13 Nov 2026

The oncology developer says emavusertib is enrolling in CLL and PCNSL, with first CLL combination data due in December 2026, while financing extends runway just into the first quarter of 2027.

Curis reported third-quarter 2026 results on 12 November 2026, showing a net loss of $8.1 million and cash of $5.0 million. The company said its funding runway now extends only into the first quarter of 2027.

Two financing steps underpin that outlook: a public offering in August 2026 and a private placement in October 2026 worth about $7.5 million.

Emavusertib, an inhibitor of IRAK4 and FLT3, is being tested with the BTK inhibitor zanubrutinib in chronic lymphocytic leukaemia (CLL). Twelve patients are enrolled so far, and Curis expects initial data in December 2026.

The drug is also being studied with ibrutinib in relapsed or refractory primary central nervous system lymphoma (PCNSL). According to the company, the US FDA and the EMA's CHMP advised in 2025 that the registrational study could support applications for accelerated approval.

In general terms, accelerated approval pathways allow conditional authorisation on the basis of surrogate or intermediate endpoints, usually with confirmatory evidence required after authorisation.

What it means for your team

  • Regulatory teams tracking PCNSL should note the company's statement that both FDA and CHMP have advised the registrational study could support accelerated approval filings.
  • The December 2026 CLL readout, from 12 enrolled patients, will be an early look at the zanubrutinib combination rather than a definitive efficacy dataset.
  • With cash of $5.0 million and runway only into Q1 2027, further financing is likely to influence development timelines and partner discussions.

Company's press release (SEC filing): Curis Inc ↗

Article written by VigiEye from the official source (Curis Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →